Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 374 followers
Latest posts
Last updated 5 days ago
Reminder: Invitation to Roche’s Half Year Results 2026 Presentation
5 days ago
Roche will publish its Half Year Results of 2026 prior to the...
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
6 days ago
Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro...
Roche receives CE Mark for blood test to identify tuberculosis infection
11 days ago
The Elecsys IGRA TB test expands global access to tuberculosis infection testing...
Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis
7 days ago
The new test enables clinicians to reliably diagnose HDV and monitor patients’...
Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
14 days ago
Five oral presentations in a Featured Research Session will highlight trontinemab, including...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
19 days ago
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated...
FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
21 days ago
The filing application is based on improvements seen across key efficacy endpoints...
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
22 days ago
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost...
Invitation to Roche’s Half Year Results 2026 Presentation
28 days ago
Roche will publish its Half Year Results of 2026 prior to the...
FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
about 1 month ago
Filing acceptance based on data from the phase III SUNMO study where...
FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer
about 1 month ago
Filing acceptance is based on the phase III Alliance ATOMIC study showing...
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
about 1 month ago
Agreement offers potential best-in-class targeted protein degrader therapy option for people living...